45. Salvaterra C., Rubin L.J. Investigationand management of pulmonary hypertension in chronic obstructive pulmonary disease // Am. Resp. Dis.– 1993.– 148.– Р. 1414-1417.
46. Sastry B.K., Narasimhan C., Reddy N.K. et al. Clinical efficacy of sildenafil in primary pulmonary hypertension a randomized, plcebocontrolled, double-blind, crossover study // J. Am. Coll Cardiol.– 2004.– Vol. 43.– P. 1149-1153.
47. Simonneau G., Galie N., Rubin. et al. Clinical classification of pulmonary hypertension // J. Am. Coll. Cardiol.– 2004.– 43 (12, suppl. S) .– P. 5S-12S.
48. Sitbon O., Humbert M., Jais X. et al. Long-term response calcium channel blockers in idiopathic pulmonary arterial hypertension // Circulation.– 2005.– Vol. 11.– P. 3105-3111.
49. The Task Force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension // Eur. Heart J.– 2004.– Vol. 24, 25.– P. 2243-2278.
50. VahanianА. Balloon valvuloplasty // Heart.– 2001.– Vol. 85, N 2.– P. 223-228.
51. Voody E.J., Simon B.A., Johns R.A. Oxygen, carbon dioxide, nitric oxide and helium // Goodman & Gilman's The pharmacological basis of therapeutics / Ed. by J.G. Hardman, L.E. Limbird.– 10th ed.– New York, 2001.– P. 385-397.
52. Wagenwoort C.A.,Wagewoort N. Primary pulmonary hypertension, a pathologic study of the lung vessels in 156 clinically diagnosed cases // Circulation.– 1970.– 42.– 1163-1184.
53. Wilkins M.R.,Paul G.A., Strange J.W. et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study // Am. J. Respir. Crit. Care Med.– 2005.– Vol. 171.– P. 1292-1297.
